Guidelines for the clinical application of the Xihuang pill for the prevention and treatment of breast hyperplasia diseases
Context The Xihuang pill (XHP) is a traditional Chinese medicine formulation that has been historically used in the prevention and treatment of proliferative breast diseases. However, there is a lack of guidelines that offer recommendations for its clinical use.Objective The task force from the Chin...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Pharmaceutical Biology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/13880209.2024.2350233 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846136279630086144 |
|---|---|
| author | Hongmei Tang Qin Lu Shiyin Feng Zhiwei Xiao Wanyin Wu Gaofeng Chen Li Deng Tianqi Yu Junyan Wu Hua Lin Bo Ji Jietao Lin Chengguang Zhang Liming Li Tao Liu Yong Ouyang Kaijun Lei Jun Chen Weiwen Peng Zhenwen Qiu Qingqun Cai Qi Liang Cuiling Liu Yuzhen Li Lixia Zhu Zexin Zhang Xueting Liu Lizhu Lin Zhihua Zheng |
| author_facet | Hongmei Tang Qin Lu Shiyin Feng Zhiwei Xiao Wanyin Wu Gaofeng Chen Li Deng Tianqi Yu Junyan Wu Hua Lin Bo Ji Jietao Lin Chengguang Zhang Liming Li Tao Liu Yong Ouyang Kaijun Lei Jun Chen Weiwen Peng Zhenwen Qiu Qingqun Cai Qi Liang Cuiling Liu Yuzhen Li Lixia Zhu Zexin Zhang Xueting Liu Lizhu Lin Zhihua Zheng |
| author_sort | Hongmei Tang |
| collection | DOAJ |
| description | Context The Xihuang pill (XHP) is a traditional Chinese medicine formulation that has been historically used in the prevention and treatment of proliferative breast diseases. However, there is a lack of guidelines that offer recommendations for its clinical use.Objective The task force from the Chinese Guangdong Pharmaceutical Association aims to develop evidence-based guidelines for XHP to prevent and treat proliferative breast diseases.Methods We searched six Chinese and English electronic databases, including the China National Knowledge Infrastructure, the Chinese Scientific Journal Database, the Wanfang Medical Database, PubMed, and Embase, up to November 1, 2022. Publications (case reports, clinical observation, clinical trials, reviews) on using XHP to treat proliferative breast diseases were manually searched. The search terms were Xihuang pill, hyperplasia of the mammary gland, breast lump, and mastalgia. The writing team developed recommendations based on the best available evidence.Results Treatment should be customized based on syndrome identification. We recommend using XHP for the prevention and treatment of breast hyperplasia disease when a patient presents the following syndromes: concurrent blood stasis syndrome, concurrent phlegm-stasis syndrome, and concurrent liver fire syndrome. Safety indicators, including blood analysis and liver and kidney function monitoring, should be performed regularly during treatment.Conclusions Current clinical evidence suggests that XHP can be used as a standalone treatment or in conjunction with other medications to prevent and manage breast hyperplasia diseases. More randomized controlled studies are warranted to establish high-quality evidence of its use. |
| format | Article |
| id | doaj-art-d876a83d78b542b48da286f7185304dc |
| institution | Kabale University |
| issn | 1388-0209 1744-5116 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Pharmaceutical Biology |
| spelling | doaj-art-d876a83d78b542b48da286f7185304dc2024-12-09T07:41:45ZengTaylor & Francis GroupPharmaceutical Biology1388-02091744-51162024-12-0162147247910.1080/13880209.2024.2350233Guidelines for the clinical application of the Xihuang pill for the prevention and treatment of breast hyperplasia diseasesHongmei Tang0Qin Lu1Shiyin Feng2Zhiwei Xiao3Wanyin Wu4Gaofeng Chen5Li Deng6Tianqi Yu7Junyan Wu8Hua Lin9Bo Ji10Jietao Lin11Chengguang Zhang12Liming Li13Tao Liu14Yong Ouyang15Kaijun Lei16Jun Chen17Weiwen Peng18Zhenwen Qiu19Qingqun Cai20Qi Liang21Cuiling Liu22Yuzhen Li23Lixia Zhu24Zexin Zhang25Xueting Liu26Lizhu Lin27Zhihua Zheng28The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaGuangdong Provincial Hospital of Chinese Medicine, Guangzhou, ChinaGuangdong Second Traditional Chinese Medicine Hospital, Guangzhou, ChinaThe Affiliated Traditional Chinese Medicine Hospital of Guangzhou Medical University, Guangzhou, ChinaThe Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaGuangdong Provincial Hospital of Chinese Medicine, Guangzhou, ChinaChinese PLA General Hospital of Southern Theater Command, Guangzhou, ChinaThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaGuangdong Second Traditional Chinese Medicine Hospital, Guangzhou, ChinaThe Affiliated Traditional Chinese Medicine Hospital of Guangzhou Medical University, Guangzhou, ChinaSun Yat-sen University Cancer Center, Guangzhou, ChinaGuangzhou Hospital of Integrated Traditional and Western Medicine, Guangzhou, ChinaFoshan Hospital of Traditional Chinese Medicine, Foshan, ChinaShenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaZhongshan Hospital of Traditional Chinese Medicine, Zhongshan, ChinaThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaShenzhen Bao’an Traditional Chinese Medicine Hospital Group, Shenzhen, ChinaShenzhen Bao’an Traditional Chinese Medicine Hospital Group, Shenzhen, ChinaThe Eighth Affiliated Hospital, Sun Yat-sen University, Guangzhou, ChinaThe Eighth Affiliated Hospital, Sun Yat-sen University, Guangzhou, ChinaThe First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, ChinaThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaGuangdong Pharmaceutical Association, Guangzhou, ChinaContext The Xihuang pill (XHP) is a traditional Chinese medicine formulation that has been historically used in the prevention and treatment of proliferative breast diseases. However, there is a lack of guidelines that offer recommendations for its clinical use.Objective The task force from the Chinese Guangdong Pharmaceutical Association aims to develop evidence-based guidelines for XHP to prevent and treat proliferative breast diseases.Methods We searched six Chinese and English electronic databases, including the China National Knowledge Infrastructure, the Chinese Scientific Journal Database, the Wanfang Medical Database, PubMed, and Embase, up to November 1, 2022. Publications (case reports, clinical observation, clinical trials, reviews) on using XHP to treat proliferative breast diseases were manually searched. The search terms were Xihuang pill, hyperplasia of the mammary gland, breast lump, and mastalgia. The writing team developed recommendations based on the best available evidence.Results Treatment should be customized based on syndrome identification. We recommend using XHP for the prevention and treatment of breast hyperplasia disease when a patient presents the following syndromes: concurrent blood stasis syndrome, concurrent phlegm-stasis syndrome, and concurrent liver fire syndrome. Safety indicators, including blood analysis and liver and kidney function monitoring, should be performed regularly during treatment.Conclusions Current clinical evidence suggests that XHP can be used as a standalone treatment or in conjunction with other medications to prevent and manage breast hyperplasia diseases. More randomized controlled studies are warranted to establish high-quality evidence of its use.https://www.tandfonline.com/doi/10.1080/13880209.2024.2350233Clinical guidelinetraditional Chinese medicinesyndrome differentiation |
| spellingShingle | Hongmei Tang Qin Lu Shiyin Feng Zhiwei Xiao Wanyin Wu Gaofeng Chen Li Deng Tianqi Yu Junyan Wu Hua Lin Bo Ji Jietao Lin Chengguang Zhang Liming Li Tao Liu Yong Ouyang Kaijun Lei Jun Chen Weiwen Peng Zhenwen Qiu Qingqun Cai Qi Liang Cuiling Liu Yuzhen Li Lixia Zhu Zexin Zhang Xueting Liu Lizhu Lin Zhihua Zheng Guidelines for the clinical application of the Xihuang pill for the prevention and treatment of breast hyperplasia diseases Pharmaceutical Biology Clinical guideline traditional Chinese medicine syndrome differentiation |
| title | Guidelines for the clinical application of the Xihuang pill for the prevention and treatment of breast hyperplasia diseases |
| title_full | Guidelines for the clinical application of the Xihuang pill for the prevention and treatment of breast hyperplasia diseases |
| title_fullStr | Guidelines for the clinical application of the Xihuang pill for the prevention and treatment of breast hyperplasia diseases |
| title_full_unstemmed | Guidelines for the clinical application of the Xihuang pill for the prevention and treatment of breast hyperplasia diseases |
| title_short | Guidelines for the clinical application of the Xihuang pill for the prevention and treatment of breast hyperplasia diseases |
| title_sort | guidelines for the clinical application of the xihuang pill for the prevention and treatment of breast hyperplasia diseases |
| topic | Clinical guideline traditional Chinese medicine syndrome differentiation |
| url | https://www.tandfonline.com/doi/10.1080/13880209.2024.2350233 |
| work_keys_str_mv | AT hongmeitang guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT qinlu guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT shiyinfeng guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT zhiweixiao guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT wanyinwu guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT gaofengchen guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT lideng guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT tianqiyu guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT junyanwu guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT hualin guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT boji guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT jietaolin guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT chengguangzhang guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT limingli guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT taoliu guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT yongouyang guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT kaijunlei guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT junchen guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT weiwenpeng guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT zhenwenqiu guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT qingquncai guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT qiliang guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT cuilingliu guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT yuzhenli guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT lixiazhu guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT zexinzhang guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT xuetingliu guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT lizhulin guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases AT zhihuazheng guidelinesfortheclinicalapplicationofthexihuangpillforthepreventionandtreatmentofbreasthyperplasiadiseases |